These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20046067)

  • 1. [Creation of TNFR1-selective antagonist and its therapeutic effects].
    Nomura T; Abe Y; Yoshioka Y; Nakagawa S; Tsunoda S; Tsutsumi Y
    Yakugaku Zasshi; 2010 Jan; 130(1):63-8. PubMed ID: 20046067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
    Mukai Y; Shibata H; Nakamura T; Yoshioka Y; Abe Y; Nomura T; Taniai M; Ohta T; Ikemizu S; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
    J Mol Biol; 2009 Jan; 385(4):1221-9. PubMed ID: 19084540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.
    Nomura T; Abe Y; Kamada H; Inoue M; Kawara T; Arita S; Furuya T; Minowa K; Yoshioka Y; Shibata H; Kayamuro H; Yamashita T; Nagano K; Yoshikawa T; Mukai Y; Nakagawa S; Tsunoda S; Tsutsumi Y
    Pharmazie; 2010 Feb; 65(2):93-6. PubMed ID: 20225650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of Tumor necrosis factor receptor-1 (TNFR1) for the treatment of autoimmune diseases.
    Zhang N; Wang Z; Zhao Y
    Cytokine Growth Factor Rev; 2020 Oct; 55():80-85. PubMed ID: 32327345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics.
    Inoue M; Tsuji Y; Yoshimine C; Enomoto S; Morita Y; Osaki N; Kunishige M; Miki M; Amano S; Yamashita K; Kamada H; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2020 Jul; 295(28):9379-9391. PubMed ID: 32398258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist.
    Shibata H; Yoshioka Y; Ohkawa A; Minowa K; Mukai Y; Abe Y; Taniai M; Nomura T; Kayamuro H; Nabeshi H; Sugita T; Imai S; Nagano K; Yoshikawa T; Fujita T; Nakagawa S; Yamamoto A; Ohta T; Hayakawa T; Mayumi T; Vandenabeele P; Aggarwal BB; Nakamura T; Yamagata Y; Tsunoda S; Kamada H; Tsutsumi Y
    J Biol Chem; 2008 Jan; 283(2):998-1007. PubMed ID: 18003610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning.
    Abe Y; Yoshikawa T; Inoue M; Nomura T; Furuya T; Yamashita T; Nagano K; Nabeshi H; Yoshioka Y; Mukai Y; Nakagawa S; Kamada H; Tsutsumi Y; Tsunoda S
    Biomaterials; 2011 Aug; 32(23):5498-504. PubMed ID: 21546081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification.
    Inoue M; Ando D; Kamada H; Taki S; Niiyama M; Mukai Y; Tadokoro T; Maenaka K; Nakayama T; Kado Y; Inoue T; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2017 Apr; 292(16):6438-6451. PubMed ID: 28235800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of New Biologics through Creation of a Functional Cytokine Mutant].
    Kamada H
    Yakugaku Zasshi; 2015; 135(7):843-9. PubMed ID: 26135083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2.
    Shibata H; Abe Y; Yoshioka Y; Nomura T; Sato M; Kayamuro H; Kawara T; Arita S; Furuya T; Nagano K; Yoshikawa T; Kamada H; Tsunoda S; Tsutsumi Y
    Cytokine; 2010 Apr; 50(1):75-83. PubMed ID: 20045350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.
    Nomura T; Abe Y; Kamada H; Shibata H; Kayamuro H; Inoue M; Kawara T; Arita S; Furuya T; Yamashita T; Nagano K; Yoshikawa T; Yoshioka Y; Mukai Y; Nakagawa S; Taniai M; Ohta T; Serada S; Naka T; Tsunoda S; Tsutsumi Y
    J Control Release; 2011 Jan; 149(1):8-14. PubMed ID: 20036293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
    Qin W; Feng J; Li Y; Lin Z; Shen B
    Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNFR1 and TNFR2 differentially mediate TNF-α-induced inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes.
    Zhang H; Xiao W
    Cell Biol Int; 2017 Apr; 41(4):415-422. PubMed ID: 28150360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension.
    Goodall LJ; Ovecka M; Rycroft D; Friel SL; Sanderson A; Mistry P; Davies ML; Stoop AA
    PLoS One; 2015; 10(9):e0137065. PubMed ID: 26352810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration.
    Dong Y; Fischer R; Naudé PJ; Maier O; Nyakas C; Duffey M; Van der Zee EA; Dekens D; Douwenga W; Herrmann A; Guenzi E; Kontermann RE; Pfizenmaier K; Eisel UL
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12304-12309. PubMed ID: 27791020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.
    Kontermann RE; Münkel S; Neumeyer J; Müller D; Branschädel M; Scheurich P; Pfizenmaier K
    J Immunother; 2008 Apr; 31(3):225-34. PubMed ID: 18317365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells.
    Rossol M; Meusch U; Pierer M; Kaltenhäuser S; Häntzschel H; Hauschildt S; Wagner U
    J Immunol; 2007 Sep; 179(6):4239-48. PubMed ID: 17785864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evoked pain behavior and spinal glia activation is dependent on tumor necrosis factor receptor 1 and 2 in a mouse model of bone cancer pain.
    Geis C; Graulich M; Wissmann A; Hagenacker T; Thomale J; Sommer C; Schäfers M
    Neuroscience; 2010 Aug; 169(1):463-74. PubMed ID: 20417692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of Evidence for a Direct Interaction of Progranulin and Tumor Necrosis Factor Receptor-1 and Tumor Necrosis Factor Receptor-2 From Cellular Binding Studies.
    Lang I; Füllsack S; Wajant H
    Front Immunol; 2018; 9():793. PubMed ID: 29740434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy.
    Fujisawa S; Konnai S; Okagawa T; Maekawa N; Tanaka A; Suzuki Y; Murata S; Ohashi K
    BMC Vet Res; 2019 Feb; 15(1):68. PubMed ID: 30819151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.